Henri Termeer joins Prosensa as Strategic Advisor

Archive

« Older Entries Newer Entries »

Prosensa Announces Progress on Exon Skipping Compounds for the Treatment of Duchenne Muscular Dystrophy Tuesday, October 23rd, 2012

£10m in milestone payments received from GlaxoSmithKline Leiden, The Netherlands, 23 October 2012 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high [...]

Menzis investeert met LSP Health Economics Fund in zorginnovaties Friday, October 19th, 2012

Amsterdam, 19 oktober 2012 – Dit voorjaar werd het LSP Health Economics Fund (LSP-HEF) opgericht. Dit fonds investeert in internationale technologiebedrijven die producten ontwikkelen die de kwaliteit van de gezondheid [...]

LSP exits BMEYE to Edwards Lifesciences Thursday, October 11th, 2012

LSP is proud to announce that it has sold its portfolio company BMEYE to Edwards Lifesciences. Details can be read in the below press release. LSP has been the largest shareholder in BMEYE since 2006. Rene Kuijten, gener [...]

Curetis Completes Enrollment for its EU Trial As Planned Tuesday, October 9th, 2012

Prospective multi-center trial enrolls 800 patient samples in 7 months Holzgerlingen (Germany), October 9, 2012 -- Curetis AG today announced it has completed enrollment for the European clinical trial of its Unyvero� [...]

Hybrigenics : green light for two European patents protecting new oral formulations of inecalcitol Tuesday, October 9th, 2012

Hybrigenics obtains patent protection until 2031 for innovative oral formulations optimized for the delivery of high doses of inecalcitol Paris, October 9th, 2012 – Hybrigenics (ALHYG), a bio-pharmaceutical company [...]

Affimed raises EUR 15.5 million in a Series D financing round Monday, October 8th, 2012

Heidelberg, Germany; October 8, 2012: Affimed Therapeutics AG, the therapeutic TandAb antibody company, today announced the successful closing of a Series D financing round of € 15.5 million. The proceeds from this tra [...]

RuiYi (formerly Anaphore) and arGEN-X Announce Exclusive Worldwide License Agreement for ARGX-109, a Novel anti-IL-6 Antibody Thursday, October 4th, 2012

Initial Development Strategy for Highly Potent Antibody Will be Focused on China LA JOLLA, CA, BREDA, THE NETHERLANDS, and GHENT, BELGIUM October 4, 2012 – RuiYi (formerly Anaphore) and arGEN-X BV announced today th [...]

Lonza and Celladon Announce Manufacturing Agreement for MYDICAR® Tuesday, October 2nd, 2012

Agreement will support future clinical trials of Celladon's product candidate MYDICAR® for the treatment of advanced heart failure. HOUSTON and SAN DIEGO, Oct. 2, 2012 /PRNewswire/ -- Lonza, a global leader in the fi [...]

LSP Health Economics Fund co-leads $28 Million Series C Financing round of IlluminOss Friday, September 28th, 2012

Amsterdam - Boston – September 28, 2012 – LSP Health Economics Fund is pleased to announce that it has made its first investment in the series C financing of IlluminOss Medical, Inc. This company is pioneering photod [...]

Curetis AG Signs Up BioLine LLC as Exclusive Distribution Partner for Russia Thursday, September 27th, 2012

Partners to start registration process and market launch in Russia Holzgerlingen, Germany, September 27, 2012 -- Curetis AG today announced that it has signed up BioLine LLC as an exclusive distribution partner for Ru [...]

« Older Entries Newer Entries »

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

back to archive overview

Archive

Archive

MONTHLY REPORTS